PHASE 1 TRIAL FOR A THERAPEUTIC MONOCLONAL ANTIBODY FOR CHIKUNGUNYA VIRUS

基孔肯雅病毒治疗性单克隆抗体的第一阶段试验

• 批准号: 10892414
• 负责人: KRISTIE MILLER
• 金额: $ 279.18万
• 依托单位: PPD DEVELOPMENT LP
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-29 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10892414
• 关键词: Chikungunya virus; Clinical Trials Unit; Communicable Diseases; Evaluation; Intervention; Investigation; New Agents; Prevention; Therapeutic Monoclonal Antibodies; clinical trial implementation; early phase clinical trial; phase I trial

The Early Phase Clinical Trial Units provide a vehicle for investigation of new agents in the treatment and prevention of infectious diseases, and can carry out all aspects of interventional clinical trial implementation.

早期临床试验单位为传染病治疗和预防方面的新药研究提供了载体，可以开展介入性临床试验实施的各个环节。